{"id":10194,"date":"2026-10-02T10:33:19","date_gmt":"2026-10-02T09:33:19","guid":{"rendered":"https:\/\/www.library.sath.nhs.uk\/research\/?p=10194"},"modified":"2026-10-02T10:33:19","modified_gmt":"2026-10-02T09:33:19","slug":"the-uk-vedolizumab-real-life-experience-study-in-inflammatory-bowel-disease-vest-patient-characteristics-drug-persistence-and-patient-centred-outcomes-2026","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2026\/10\/02\/the-uk-vedolizumab-real-life-experience-study-in-inflammatory-bowel-disease-vest-patient-characteristics-drug-persistence-and-patient-centred-outcomes-2026\/","title":{"rendered":"The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes (2026)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Type of publication:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Journal article<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Author(s):<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bodger, Keith; Booker, Cheryl; Taylor, Frederick; Ahmad, Tariq; Bloom, Stuart; *Butterworth, Jeffrey; Kok, Klaartje; Lobo, Alan; Irving, Peter; Cummings, J R Fraser.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Citation:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Therapeutic Advances in Gastroenterology. 19:17562848261446551, 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Abstract:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Background: VEST was a multi-centre study of real-world use of vedolizumab in inflammatory bowel disease (IBD) in routine practice in the United Kingdom.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Objectives: To describe real-world indications, effectiveness, patient-reported outcomes and safety.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Design: Prospective observational cohort study at 22 centres.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Methods: Patients receiving vedolizumab as part of standard care were included. Data were collected at infusion visits for activity indices (Harvey-Bradshaw Index (HBI) or partial Mayo Score (PMS)), physician global assessment (PGA), patient-reported quality-of-life and treatment perception (IBD-Control Questionnaire) and adverse events. Clinical response (Wk14) was defined as a reduction in HBI 3 or PMS 2, clinical remission as HBI 4 or PMS 1 and analysed using non-responder imputation. One-year persistence was defined as continuing on vedolizumab after an infusion at 48 weeks. Biomarker and endoscopic data were not available.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Results: 364 patients, mean age: 48 years; 132 (36%) with Crohn's disease (CD), 224 (62%) with UC and 8 (2%) with IBD-U; 174 (48%) male; 142 (39%) receiving steroids at baseline (Wk0); 141 (39%) bio-naive. At baseline, 279 (77%) had \"active\" disease. One-year persistence: 58% overall (54% for active disease). Among persistent cases (n = 212), median (IQR) IBD-Control-8 scores improved from 6 (3-10) at baseline to 14 (10-16) at post-induction (Wk14) and 1 year (p &lt; 0.001 vs baseline). Corresponding scores for IBD-Control-VAS were: 50 (30-70), 80 (65-90) and 85 (70-95), respectively (p &lt; 0.001 vs baseline). Each domain of IBD-Control-8 showed improvement. Baseline and post-induction health status (activity index, PGA or IBD-Control) were associated with 1-year persistence, but no significant associations were observed for disease type, duration, bio-naive status or baseline steroids. Of those with active disease at Wk0, clinical remission rates were 29%, 30% and 38% for CD, UC and IBD-U, respectively, and steroid-free remission rates were 26%, 27% and 38%. Similar remission rates were observed at 1 year. Possible adverse events leading to treatment cessation were rare (3%).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Conclusion: In routine clinical practice in the UK, vedolizumab demonstrated high levels of persistence. Similar rates of clinical response, remission and 1-year persistence were seen in UC and CD patients, and in bio-experienced versus naive cases. Persistent cases experienced significant and sustained improvements in quality of life and treatment perception. Persistence does not imply anti-inflammatory efficacy, as biomarker data were not available.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DOI:<\/strong> 10.1177\/17562848261446551<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261446551\">Link to full-text<\/a> [open access - no password required]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Journal article Author(s): Bodger, Keith; Booker, Cheryl; Taylor, Frederick; Ahmad, Tariq; Bloom, Stuart; *Butterworth, Jeffrey; Kok, Klaartje; Lobo, Alan; Irving, Peter; Cummings, J R Fraser. Citation: Therapeutic Advances in Gastroenterology. 19:17562848261446551, 2026. Abstract: Background: VEST was a<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2026\/10\/02\/the-uk-vedolizumab-real-life-experience-study-in-inflammatory-bowel-disease-vest-patient-characteristics-drug-persistence-and-patient-centred-outcomes-2026\/\">Read more <span class=\"screen-reader-text\">The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes (2026)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1001,200],"tags":[1106,221,1002],"class_list":["post-10194","post","type-post","status-publish","format-standard","hentry","category-open-access","category-staff-publication","tag-1106","tag-gastroenterology","tag-gold-open-access"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/10194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=10194"}],"version-history":[{"count":1,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/10194\/revisions"}],"predecessor-version":[{"id":10195,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/10194\/revisions\/10195"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=10194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=10194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=10194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}